Testing 11 New Synthetic Cannabinoids: Most Were More Potent Than THC

Behavioral pharmacology study testing 11 DEA-identified synthetic cannabinoids. Locomotor activity measured in Swiss-Webster mice. Drug discrimination conducted in Sprague-Dawley rats trained to discriminate THC. ED50 values calculated for each compound relative to THC in both assays.

Synthetic cannabinoids continue to cause hospitalizations and deaths because users cannot predict their potency. This study provides the first systematic potency comparison for 11 specific compounds the DEA has flagged as concerning — giving clinicians, toxicologists, and poison control centers reference data for treating exposures.

This adds to the semi-synthetic cannabinoid picture (RTHC-00234) by characterizing a different class — fully synthetic cannabinoids with novel chemical scaffolds. While RTHC-00234 focused on HHC and hemp-derived semi-synthetics in Europe, this study addresses the more dangerous fully synthetic compounds that continue to appear in the US drug supply. The finding that most are more potent than THC explains why synthetic cannabinoid exposures produce more severe clinical presentations than natural cannabis.

Rodent behavioral models may not perfectly predict human pharmacological responses. Only two behavioral measures tested — other important properties (duration of action, receptor binding profiles, toxicity) were not assessed. The ED50 comparisons provide relative potency but don't directly translate to human dosing. New synthetic cannabinoids appear faster than they can be characterized.